Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials.
about
24-h Efficacy of Glaucoma Treatment OptionsManaging adverse effects of glaucoma medicationsEfficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension.An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan(®) RC Early Analysis Review (CLEAR) trialClinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertensionWhat comparative effectiveness research is needed? A framework for using guidelines and systematic reviews to identify evidence gaps and research priorities.Comparing the efficacy of latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%), and timolol (0.5%) in the treatment of primary open angle glaucomaEffects of prostaglandin analogues on aqueous humor outflow pathways.A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprostEfficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews.Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical settingIntraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol.Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.Initial Treatment: Prostaglandin Analog or Selective Laser TrabeculoplastyNetwork Meta-analysis for Clinical Practice Guidelines: A Case Study on First-Line Medical Therapies for Primary Open-Angle Glaucoma.Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension.Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study.Quality of life of glaucoma patients under medical therapy with different prostaglandins.An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial.Citation of previous meta-analyses on the same topic: a clue to perpetuation of incorrect methods?Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost.Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trialOcular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes.Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprostTwenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressurePharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides.Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study.Role of fixed combinations in the management of open-angle glaucoma.Demonstration of an online tool to assist managed care formulary evidence-based decision making: meta-analysis of topical prostaglandin analog efficacy.A review of the use of latanoprost for glaucoma since its launch.Ocular surface cytotoxicity and safety evaluation of tafluprost, a recently developed anti-glaucoma prostaglandin analog.Latanoprost in the treatment of glaucoma.Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials.Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors.Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK).Microarray-based analysis of gene expression profiles in peripheral blood of patients with acute primary angle closure.Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma.Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice.
P2860
Q26766594-302329A6-4EFF-4A7B-9878-893BEC596982Q28240902-8C10C308-5E7C-4F9E-99F6-7E9265706A7AQ30435051-2E661D58-7487-455C-B376-4BF505EDB2B6Q33706842-F1618DA8-FC04-4AA7-ADC3-18203A2219DBQ34043309-8F0DC7F0-E0BF-4F5C-BB44-58B7FF71BE1FQ34258967-8FDBA2FE-A4CF-4CA5-9795-8670CEEF3EE1Q34263238-9C43F2EA-7D26-45CB-957D-A095A3A32E8BQ34393424-4125D2C1-E748-4B84-B7EE-40916478AD73Q34399842-34029EF4-5DAB-45E9-812D-061A256AEA1DQ34492862-1E874B8A-8C61-4D89-B3F4-D82EFBD6841BQ34901153-4FCA537D-D08F-4FF3-993C-BA880E727FCAQ35102806-A5E37BAE-DBFE-4437-A41D-9268917F415DQ35237431-D90BD1EB-3807-4C90-9442-0EB06D383164Q35617544-4A112795-9D19-4D8E-A995-010E5388BD3BQ35840205-F180F596-0F60-423B-8142-67F5A7FF33D8Q35964378-318C6DBA-8BE9-4BF6-8335-1E0899917015Q35992361-6FD90347-AFA1-48E0-9F5F-B77BB5C6DDB2Q35997507-19601230-A524-4D3F-A3C0-6B6876EF700CQ36134942-E143020C-2843-4853-A5FD-8BEEA9C82AE2Q36396950-8643F446-6CA8-4FF3-AB39-4A00E41C99A9Q36487013-8167521A-4F6D-4CC9-BB75-8438194F537FQ36513394-AF8D74AD-E897-482E-A4FA-2B0CB298068DQ36709208-4EC67F85-ABED-44B6-ACDA-59FBA59DA19AQ37030839-F07AD0AD-1F62-4C1D-98DE-BDD61CBFAD32Q37079208-15E8FEF3-6583-47BB-AA36-50ACF56A1DE6Q37376684-BF003F04-9BAE-4404-BC9C-2F89AE637B9AQ37634184-CCE955EA-DA00-4D3F-B225-016E39791D0AQ37636153-EAE5F9AB-6D3C-4047-A566-8DCF4C7D99A9Q37702260-3F3E8B78-F6CD-4B4C-A2D4-8CCF194B4436Q37847155-FD9E2B46-22A1-4BA1-9402-E35721F13E7DQ37918357-49A6CB67-A97B-40BD-A773-0EC37EB95450Q37986149-E329B86E-9EE4-42AE-B6AF-BBF986103498Q38190054-D922ED1C-F9DA-4537-817B-C11C3E4DAE2AQ38261310-73362267-4CA7-42C4-8ED5-2136BAE0EBECQ38582444-C85F7D5F-824A-4E9E-A14A-CE5551C5E538Q38725839-67FD74BB-8F33-4879-8582-EB122B9F6A94Q38843414-2E192897-B1E1-4F09-A89F-3A6D551E3534Q38890553-D3F32DC8-8FD8-4A70-A7CA-F78CC1453BFDQ38934012-1BFB7AA8-529E-409C-B8AB-A4BD61F7F63AQ39348004-54E15B45-7D23-4F8F-A1D1-98B3BAE53D11
P2860
Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Efficacy and tolerability of p ...... ed controlled clinical trials.
@ast
Efficacy and tolerability of p ...... ed controlled clinical trials.
@en
type
label
Efficacy and tolerability of p ...... ed controlled clinical trials.
@ast
Efficacy and tolerability of p ...... ed controlled clinical trials.
@en
prefLabel
Efficacy and tolerability of p ...... ed controlled clinical trials.
@ast
Efficacy and tolerability of p ...... ed controlled clinical trials.
@en
P2093
P1433
P1476
Efficacy and tolerability of p ...... ed controlled clinical trials.
@en
P2093
Florent Aptel
Michel Cucherat
Philippe Denis
P304
P356
10.1097/IJG.0B013E3181666557
P577
2008-12-01T00:00:00Z